In early October, the Japanese Heart Failure Society (JHFS) held its first annual scientific meeting since it published a focused update of the heart failure treatment guidelines in March jointly with the Japanese Circulation Society. The confab featured a series…
ORGANIZATION
JPMA Renews Call for Post-Launch Innovation Review in 2021 Proposal
The Japan Pharmaceutical Manufacturers Association (JPMA) has incorporated a post-launch mechanism that could be described as “innovation re-pricing” in its policy proposal in 2021, calling for the re-evaluation of medicines that are on the market after a certain period of…
To read the full story
ORGANIZATION
- JGA Sets Out 5-Pronged Measures to Restore Trust in Generics
October 27, 2021
- Kenporen’s Masato Matsumoto to Take Over from Kono as Chuikyo Payer Rep
October 27, 2021
- Main Focus of INES Proposal Is Securing Resources to Reward Innovation, Not Macroeconomic Indexing
October 25, 2021
- Choseido Suspended from JGA for 5 Years after Biz Suspension Order
October 15, 2021
- EFPIA to Ponder Position on Macroeconomic Indexing with Patient Access as Top Priority, Continue Dialogue with Japan Govt
October 14, 2021
If you were able to make more money at a company you found less desirable than your current one, would it be worth it? Conversely, would you move to a better company and a better role and accept less pay?…
The average ratio of female employees at managerial posts stood at just 12.5% at pharmaceutical companies operating in Japan, a Jiho survey revealed. While foreign drug makers had an average 25.0%, the ratio came to as low as 9.8% for…
Biogen’s controversial Alzheimer’s drug aducanumab was filed for Japanese regulatory approval in December. If approved, it will be the first…
Japan’s key reimbursement policy panel on December 20 approved an outline of its FY2020 drug pricing reform next April, with…
Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…